Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)

Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)

US Patent 10640502 · Granted May 5, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhanc2025
Substituted [1,2,4]triazolo[4,3-c]pyrimidines that induce degradation of embryon2025
Bifunctional compounds comprising Apcin-A and their use in the treatment of canc2025
Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of in2025
Substituted fused pyrrolo-diazepinones and uses thereof2025
Substituted heterocycles as c-MYC targeting agents2024
Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhanc2024
Substituted [1,2,4]triazolo[4,3-c]pyrimidin-5-amines and proteolysis-targeting c2024
Substituted pyrrolidones and piperidones as small molecule inhibitors of EZH2 an2024
Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-2024
Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of in2023
Therapeutic targeting of the BAP1 complex in cancer2023